Literature DB >> 27884053

Disability in patients with end-stage liver disease: Results from the functional assessment in liver transplantation study.

Mariya L Samoylova1, Kenneth E Covinsky2, Marta Haftek2, Selena Kuo1, John P Roberts3, Jennifer C Lai2.   

Abstract

Cirrhosis leads to sarcopenia and functional decline that can severely impact one's ability to function at home and in society. Self-reported disability scales to quantify disability-Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL)-are validated to predict mortality in older adults. To evaluate disability in liver transplantation (LT) candidates and quantify its impact on outcomes, consecutive outpatients ≥18 years listed for LT with laboratory Model for End-Stage Liver Disease scores of ≥12 at a single high-volume US LT center were assessed for ADLs and IADLs during clinic visits. Multivariate competing risk models explored the effect of disabilities on wait-list mortality (death or delisting for illness). Of 458 patients, 36% were women, median (interquartile range [IQR]) age was 60 years (IQR, 54-64 years), and initial Model for End-Stage Liver Disease-Sodium (MELD-Na) was 17 (IQR 14-20). At first visit, 31% had lost ≥ 1 ADL, and 40% had lost ≥ 1 IADL. The most prevalent ADL deficits lost were continence (22%), dressing (12%), and transferring (11%); the most prevalent IADLs lost were shopping (28%), food preparation (23%), and medication management (22%). After adjustment for age, MELD-Na, and encephalopathy, dressing (subdistribution hazard ratio [SHR], 1.7; 95% confidence interval [CI], 1.0-2.8; P = 0.04), toileting (SHR, 1.9; 95% CI, 1.1-3.5; P = 0.03), transferring (SHR, 1.9; 95% CI, 1.1-3.0; P = 0.009), housekeeping (SHR, 1.8; 95% CI, 1.2-3.0; P = 0.009), and laundry (SHR, 2.2; 95% CI, 1.3-3.5; P = 0.002) remained independent predictors of wait-list mortality. In conclusion, ADL/IADL deficits are common in LT candidates. LT candidates would benefit from chronic disease management programs developed to address the impact of cirrhosis on their daily lives. Liver Transplantation 23 292-298 2017 AASLD.
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27884053      PMCID: PMC5325797          DOI: 10.1002/lt.24684

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  31 in total

1.  Geriatric-based versus general wards for older acute medical patients: a randomized comparison of outcomes and use of resources.

Authors:  K Asplund; Y Gustafson; C Jacobsson; G Bucht; A Wahlin; J Peterson; J O Blom; K A Angquist
Journal:  J Am Geriatr Soc       Date:  2000-11       Impact factor: 5.562

2.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

3.  Addition of frailty and disability to cardiac surgery risk scores identifies elderly patients at high risk of mortality or major morbidity.

Authors:  Jonathan Afilalo; Salvatore Mottillo; Mark J Eisenberg; Karen P Alexander; Nicolas Noiseux; Louis P Perrault; Jean-Francois Morin; Yves Langlois; Samuel M Ohayon; Johanne Monette; Jean-Francois Boivin; David M Shahian; Howard Bergman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-03-06

4.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

5.  Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization.

Authors:  Gena C Dunivan; Steve Heymen; Olafur S Palsson; Michael von Korff; Marsha J Turner; Jennifer L Melville; William E Whitehead
Journal:  Am J Obstet Gynecol       Date:  2010-03-12       Impact factor: 8.661

6.  Patient knowledge about disease self-management in cirrhosis.

Authors:  Michael L Volk; Natalie Fisher; Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2013-03       Impact factor: 10.864

7.  Efficacy of a chronic disease management model for patients with chronic liver failure.

Authors:  Alan J Wigg; Rosemary McCormick; Rachel Wundke; Richard J Woodman
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-29       Impact factor: 11.382

8.  Prevalence of incontinence in patients after stroke during rehabilitation: a multi-centre study.

Authors:  Apichana Kovindha; Pattra Wattanapan; Piyapat Dejpratham; Wutichai Permsirivanich; Vilai Kuptniratsaikul
Journal:  J Rehabil Med       Date:  2009-05       Impact factor: 2.912

9.  A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.

Authors:  M W Rich; V Beckham; C Wittenberg; C L Leven; K E Freedland; R M Carney
Journal:  N Engl J Med       Date:  1995-11-02       Impact factor: 91.245

10.  Chronic disease management for patients with cirrhosis.

Authors:  Michael L Volk; John D Piette; Amit S Singal; Anna S F Lok
Journal:  Gastroenterology       Date:  2010-05-27       Impact factor: 33.883

View more
  15 in total

1.  Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age.

Authors:  Patrick McCabe; Artin Galoosian; Robert J Wong
Journal:  Dig Dis Sci       Date:  2019-10-22       Impact factor: 3.199

2.  The Liver Frailty Index Improves Mortality Prediction of the Subjective Clinician Assessment in Patients With Cirrhosis.

Authors:  Jennifer C Lai; Kenneth E Covinsky; Charles E McCulloch; Sandy Feng
Journal:  Am J Gastroenterol       Date:  2017-12-12       Impact factor: 10.864

3.  Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice.

Authors:  Jennifer C Lai; Christopher J Sonnenday; Elliot B Tapper; Andres Duarte-Rojo; Michael A Dunn; William Bernal; Elizabeth J Carey; Srinivasan Dasarathy; Binita M Kamath; Matthew R Kappus; Aldo J Montano-Loza; Shunji Nagai; Puneeta Tandon
Journal:  Am J Transplant       Date:  2019-05-08       Impact factor: 8.086

Review 4.  Evaluation of liver transplant candidates with non-alcoholic steatohepatitis.

Authors:  James Philip G Esteban; Amon Asgharpour
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

5.  Physical frailty after liver transplantation.

Authors:  Jennifer C Lai; Dorry L Segev; Charles E McCulloch; Kenneth E Covinsky; Jennifer L Dodge; Sandy Feng
Journal:  Am J Transplant       Date:  2018-03-13       Impact factor: 8.086

6.  Frailty and Outcomes After Liver Transplantation.

Authors:  Elliot B Tapper
Journal:  Curr Transplant Rep       Date:  2019-01-14

Review 7.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

8.  The Effect of Dual Sensory Impairment and Multimorbidity Patterns on Functional Impairment: A Longitudinal Cohort of Middle-Aged and Older Adults in China.

Authors:  Qiong Wang; Shimin Zhang; Yi Wang; Dan Zhao; Xi Chen; Chengchao Zhou
Journal:  Front Aging Neurosci       Date:  2022-04-08       Impact factor: 5.702

Review 9.  Assessment of the Frail Patient With End-Stage Liver Disease: A Practical Overview of Sarcopenia, Physical Function, and Disability.

Authors:  Felicity R Williams; Don Milliken; Jennifer C Lai; Matthew J Armstrong
Journal:  Hepatol Commun       Date:  2021-02-26

10.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey
Journal:  Hepatology       Date:  2021-09       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.